[HTML][HTML] Combining enabling formulation strategies to generate supersaturated solutions of delamanid: in situ salt formation during amorphous solid dispersion …
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
[PDF][PDF] Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion …
T Van Duong, HT Nguyen, LS Taylor - European Journal of …, 2022 - academia.edu
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
[PDF][PDF] Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion …
T Van Duong, HT Nguyen… - European Journal of …, 2022 - researchgate.net
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
Combining Enabling Formulation Strategies to Generate Supersaturated Solutions of Delamanid: In Situ Salt Formation During Amorphous Solid Dispersion …
T Van Duong, HT Nguyen, L Taylor - Available at SSRN 4030295 - papers.ssrn.com
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
[HTML][HTML] Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion …
T Van Duong, HT Nguyen, LS Taylor - European Journal of …, 2022 - ncbi.nlm.nih.gov
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for …
T Van Duong, HT Nguyen… - European journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for …
TV Duong, HT Nguyen, LS Taylor - European Journal of …, 2022 - europepmc.org
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for …
TV Duong, HT Nguyen, LS Taylor - European Journal of …, 2022 - europepmc.org
Poor solubility is a major challenge that can limit the oral bioavailability of many drugs,
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …
including delamanid, a weakly basic nitro-dihydro-imidazooxazole derivative used to treat …